[Intra-lesion administration of beta-interferon in the treatment of CIN associated with HPV infection].
Thirty-two women with histologically confirmed cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection were treated with intralesional beta-interferon. At 12 months from the end of the treatment, 60% of the patients showed complete regression, histologically assessed, of CIN. Considering separately the different CIN grades, the regression for CIN I was 71%, 64% for CIN II and 45% for CIN III. Side-effects were rather frequent (84%) but they did not require discontinuation of the treatment. On the basis of these data the Authors believe that intralesional beta-interferon, in selected cases, can play a role, as a conservative modality, among the different techniques of CIN therapy.
Micheletti
L
L
Istituto di Ginecologia ed Ostetricia, Università degli Studi di Torino.
Barbero
M
M
Preti
M
M
Zanotto Valentino
M C
MC
Nicolaci
P
P
Corbella
L
L
Borgno
G
G
D000328:Adult; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D027383:Papillomaviridae; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
Il beta-interferone intralesionale nel trattamento delle CIN associate ad infezione da HPV.